体軸型脊椎関節炎 ASAS-EULAR 推奨 2022 アップデート
Ann Rheum Dis 2022; online ahead of print doi:10.1136/ard-2022-223296
Since the last update in 2016, more data have become available on existing treatment options for axSpA, and particularly on IL-17i. The increasing availability of more drugs and with different modes of action raises questions around their positioning in the treatment pathway. This review sought to update the 2016 recommendations with newly available evidence.
The 2022 update of the ASAS-EULAR recommendations provides healthcare professionals taking care of patients with axSpA, patients and other relevant stakeholders with the most up-to-date evidence and expert insights in the management of axSpA.
Keywords:
